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Purpose: Vitiligo prevalence and its associated comorbidities rate have been report-
ed variably among different populations. We aimed to determine the prevalence of 
vitiligo in Korea along with the baseline rate of comorbidities and compared the 
risks to the general population using hospital visit information of the total population 
in Korea. Materials and Methods: We assessed demographic characteristics of vit-
iligo patients in Korean population from 2009 to 2011 in a nationwide data from 
Health Insurance Review Assessment Service. Patients who had at least one visit to 
Korea’s primary, secondary, or tertiary referral hospitals with International Classifi-
cation of Diseases, 10th Revision, Clinical Modification diagnosis code for vitiligo 
were identified. As a supplementary study, comorbidities associated with vitiligo 
were selected for further review to calculate relative risks compared to the general 
population. Results: The annual prevalence of vitiligo determined by hospital-visit-
ing rate in Korea was 0.12% to 0.13% over a three year period. In sync with other 
previous epidemiological studies, there was bimodal distribution among the age 
groups and no difference between genders. Also, vitiligo in Korean population was 
associated with various autoimmune/non-autoimmune diseases such as thyroiditis, 
atopic dermatitis, and psoriasis. Conclusion: This study was by far the most compre-
hensive review on prevalence of vitiligo using a data of total population in Korea. 
The prevalence is within a range of those reported in previous literatures, and in-
creased risk of comorbidities such as thyroid diseases and psoriasis in vitiligo might 
aid clinicians in the initial work up of vitiligo patients and concurrent follow ups.
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INTRODUCTION
Vitiligo, an acquired skin disease of progressive depigmentation due to loss of epi-
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vice (HIRA) of South Korea. The HIRA database is the Na-
tional Korean Health Insurance claims database. In South 
Korea, all citizens are obligated to join the National Health 
Security System which has National Health Insurance Pro-
gram as one of its three arms.7 The insurance claims database 
holds all primary to tertiary referral hospitals’ data on inpa-
tients and outpatients, including data on diagnosis and treat-
ment costs for claims. It is already actively used as a tool for 
epidemiological studies in various medical specialties.8-10
In our study, patients who had at least one visit to Korea’s 
primary, secondary, or tertiary referral hospitals with a diag-
nosis of vitiligo according to the International Classification 
of Diseases, 10th Revision, Clinical Modification (ICD-10-
CM) were identified as vitiligo cases. We then identified co-
morbidities associated with vitiligo and compared the re-
sults with comorbidities present in the general population 
from 2009 to 2011. Information on the general population 
was obtained from Korean Statistical Information Service.11
Definition of comorbidity 
We collected patients who had at least one claim with prin-
cipal or secondary diagnosis of following selective diseases 
that are known to be associated with vitiligo. We classified 
diseases into two groups: autoimmune and non-autoim-
mune. First, autoimmune disorders, including lupus erythe-
matosus (ICD-10 codes: L93.0), dermatomyositis (ICD-10 
codes: M33.1, M33.9), scleroderma (ICD-10 codes: M34.9, 
L94.0, L94.1), rheumatoid arthritis (ICD-10 codes: M06), 
alopecia areata (ICD-10 codes: L63.9), thyroiditis (ICD-10 
codes: E06.9), multiple sclerosis (ICD-10 codes: G35), and 
insulin-dependent diabetes mellitus (ICD-10 codes: E10.61, 
E10.62) were included. For non-autoimmune disorders, 
atopic dermatitis (ICD-10 codes: L20), psoriasis (ICD-10 
codes: L40), and other comorbidities including sarcoidosis 
(ICD-10 codes: D86), Tuner syndrome (ICD-10 codes: 
Q96), anemia (ICD-10 codes: D64.9), vitamin B12 defi-
ciency anemia (ICD-10 codes: D51.9), folate deficiency 
anemia (ICD-10 codes: D52.9, D52.8) were included. 
Statistical analysis
To estimate the prevalence of vitiligo, a total number of 
physician-diagnosed vitiligo cases were identified in a year-
ly interval from 2009 to 2011. Afterwards, annual event 
rates per 100000 patients for each year were obtained by di-
viding prevalence of one year by total population of the 
same year. Then, using the raw data from HIRA, we calcu-
lated the ratio of event rates for each comorbidities/vitiligo 
dermal melanocytes, is reported with varying prevalence 
over the world. Although there is no wide fluctuation known 
among various ethnic groups in its prevalence, more evi-
dent clinical features of vitiligo in darker-skinned individu-
als lead to frequent hospital visits and treatment, raising a 
concern for social stigma.1 In various population-based 
studies, vitiligo’s worldwide prevalence was noted as 0.5% 
to 1%2 while there were also peaks up to 8%.3 The most re-
cently updated prevalence of vitiligo through screening of 
more than 50 studies worldwide reported prevalence of vit-
iligo as between 0.5 and 2%.4 However, as studies using 
entire population is lacking, preexisting studies have limita-
tions in estimating vitilligo’s worldwide prevalence. In South 
Korea, the total population is about fifty million, and all cit-
izens are obligated to join the National Health Security Sys-
tem. Within this system all information on hospital visits 
are stored and managed. Therefore, our study using medi-
cal information of total population in Korea is based on a 
good estimated prevalence of certain disease. 
Previous studies characterizing vitiligo in Korean popula-
tion was mostly limited to a survey by tertiary referral hos-
pitals at a single institution.5 A lack of a nation-wide data 
was a barrier in determining epidemiological data of vitili-
go for distribution of patients’ age and exact prevalence. 
Also, it raised a possibility of selection bias through includ-
ing only severe patients who visited university-level hospi-
tals. Hence to get a broader picture of vitiligo in Korea, we 
determined prevalence of vitiligo using a nationwide claim 
database. In addition, we performed a search on prevalence 
of commonly associated diseases in vitiligo. Autoimmune 
conditions such as thyroiditis and rheumatoid arthritis are 
major disease groups that aggravate patients’ morbidity and 
burden of disease.6 Knowledge on prevalence of comorbid-
ities in vitiligo will, therefore, provide insights into future 
management of the disease. 
The purposes of this study were to 1) estimate the preva-
lence of vitiligo in Korea and 2) compare associated co-
morbidities in vitiligo with general population of Korea us-
ing a nationwide claim database. 
MATERIALS AND METHODS
Study population
We assessed demographic characteristics of vitiligo patients 
in Korean population from 2009 to 2011, selected from a na-
tionwide data in Health Insurance Review Assessment Ser-
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total number of physician-diagnosed cases of vitiligo for 
each year are shown. Prevalence of vitiligo between 2009 
and 2011 was approximately 0.13% as a yearly rate with 
male to female ratio of 1 to 1.31 (95% CI 0.75 to 0.77). Fig. 
1 depicts prevalence by 5-year age intervals which shows 
bimodal distribution of peaks at age 5 to 15 years (16.05%) 
and 45 to 55 years (16.5%).
 
Association with comorbidities 
Table 2 presents the prevalence of comorbidities in vitiligo 
patients and it’s comparison with general population from 
year 2009 to 2011. We were not able to match vitiligo cases 
and general population’s control for gender or age. In auto-
immune disorders, vitiligo was significantly associated with 
increased relative risk [RR; (95% CI)] of lupus erythemato-
sus [21.77; (1.02‒28.17)], dermatomyositis [1.63; (1.19‒ 
3.72)], scleroderma [22.32; (1.02‒28.45)], alopecia areata 
[3.20; (1.00‒3.48)], thyroiditis [12.68; (1.00‒13.34)], and in-
sulin-dependent diabetes [1.08; (1.01‒1.28)]. There were no 
patients with both vitiligo and rheumatoid arthritis in 2009 
to calculate relative risk in comparison with general popula-
tion and also no vitiligo patients with accompanying multi-
ple sclerosis. 
Risks of comorbidities in non-autoimmune diseases are 
as follows: atopic dermatitis [2.70; (1.00‒2.79)], psoriasis 
and comorbidities/general population. Calculation of pro-
portion of two different rates was chosen as our statistical 
analysis method since case number of vitiligo patients strat-
ified into age-groups was not available. Therefore, calculat-
ed prevalence of comorbidities in vitiligo patients are not 
adjusted, but crude rates. While the prevalence rate of vitili-
go in general population was determined separately each 
year, the rates of comorbidities in vitiligo and general popu-
lation were calculated by summing up the number of cases 
from 2009 to 2011 and then averaged by three years. After 
calculating rates, relative risks (RRs) were estimated for co-
morbidities of vitiligo and general population. RR>1 indi-
cates that comorbidity event was more frequent in vitiligo 
patients than general population and RR<1 indicates co-
morbidity event less frequent in vitiligo group than general 
population. 95% confidence intervals (CIs) for the RRs 
were also calculated using the following equation: CI of 
RR=eln(RR)-1.96√ln(RR), eln(RR)+1.96√ln(RR). CI for sex ratio was cal-
culated using exact binomial method. 
RESULTS
 
Prevalence and demographics 
Table 1 shows demographic characteristics of the cases. A 
Table 1. Demographic of Vitiligo Patients in Korea 
2009 2010 2011
n % n % n %
Total 61348 0.12 63829 0.13 65224 0.13 
Gender
    Male 26535 0.05 27534 0.05 28289 0.05 
    Female 34813 0.07 36295 0.07 36935 0.07 
Age 
    <20 16427 0.03 17046 0.03 17670 0.03
    20‒39 14277 0.03 14333 0.03 14281 0.03 
    40‒59 18580 0.04 19534 0.04 19799 0.04
    ≥60 12064 0.02 12916 0.03 13474 0.03 
Fig. 1. Age distribution of vitiligo patients in Korean population. 
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as well as from other western countries. However, because 
disease burden might vary among different skin-colored 
population, we deemed it more appropriate to compare our 
prevalence data with those from other Asian countries.
A study on prevalence of dermatological disorders in Ja-
pan, performed as a nationwide, cross-sectional, seasonal, 
multicenter, hospital-based study, and conducted amongst 
64448 cases, reported prevalence of vitiligo as 1.68%.12 But 
this study was merely a measure of skin disorders in patients 
attending dermatology clinics, and the actual prevalence 
might be lower if prevalence was based on general popula-
tion. Population survey in China, performed as a door-to-
door survey in Shaanxi Province for 42833 cases, identified 
vitiligo prevalence to be 0.093%,13 and another study in the 
countryside of China’s Jiangsu Province reported prevalence 
between 0.09‒0.15%.14 There was also a study with higher 
prevalence among 47490 people‒1.9%‒in Anhui province, 
China.15 
Comparing to other Asian countries, Korea’s prevalence 
was lower than that of Japan’s, but similar to two of China’s 
epidemiology studies noted thus far. Our study was conduct-
ed using a methodology different from China’s door-to-door 
survey, nevertheless, we provided a fresh insight of com-
paring vitiligo between similar regions, considering genetic 
factors and skin phototype into account. 
[5.76; (1.00‒6.11)], sarcoidosis [2.61; (1.24‒6.47)], Turner 
syndrome [5.38; (1.10‒9.92)], anemia [1.69; (1.07‒2.78)], 
vitamin B12 deficiency anemia [2.23; (1.12‒4.29)], and fo-
late deficiency anemia [1.25; (1.17‒2.73)]. 
DISCUSSION
The most comprehensive review of vitiligo prevalence re-
ported thus far by Krüger and Schallreuter4 lists searches of 
more than 50 studies. While studies collected by Krüger and 
Schallreuter4 did not follow unified methods and some were 
based on subgroups rather than general population, it report-
ed a reasonably acceptable prevalence of vitiligo, at around 
0.5% to 2%. 
Our study is the first study to date that provides a national-
ly representative data on prevalence of vitiligo in Korea. The 
prevalence determined by a hospital-visiting rate in Korea 
was 0.12% to 0.13% over a three year period. The rationale 
for observing a three year period was to compensate for pos-
sible omission of cases who might not visit a clinic in one 
year period. Since there was no dramatic change in preva-
lence over the three years, 0.13% seems reliable as a repre-
sentation of prevalence in Korea. Our reported prevalence 
is lower than the one reported by Krüger and Schallreuter4 
Table 2. Rate per 100000 and RR in Vitiligo Patients Compared to General Population for Associated Comorbidities, Divided into 
Autoimmune and Non-Autoimmune Disorders
Disorders
2009 2010 2011
RR 95% CI
Vitiligo General population Vitiligo
General 
population Vitiligo
General 
population
Autoimmune disorders
    Lupus erythematosus 76.612 4.335 97.135 4.213 105.789 4.335 21.77   1.02‒28.17
    Dermatomyositis 4.89 4.054 9.4 4.262 12.265 8.097   1.63 1.19‒3.72
    Scleroderma 99.433 4.48 109.668 4.642 107.322 5.064 22.32   1.02‒28.45
    Rhematoid arthritis 0 506.571 1.567 446.802 1.533   439.888
    Alopecia areata 570.516 270.853 1023.046 270.338 1044.094   287.582 3.2       1‒3.48
    Thyroiditis 1478.451 186.647 2754.234 210.319 2839.446   164.524 12.68         1‒13.34
    Multiple sclerosis 0 4.363 0 0 0 0
    Insulin-dependent diabetes 172.785 201.532 267.903 192.904 213.112   210.607   1.08  1.01‒1.28
Non-autoimmune disorders
    Atopic dermatitis 4140.314 2091.337 6451.613 2074.467 5947.197 1984.981 2.7       1‒2.79
    Psoriasis 1431.18 311.457 2058.625 307.041 1833.681   308.61   5.76       1‒6.11
    Sarcoidosis 4.89 2.565 12.533 2.736 4.6       3.159   2.61  1.24‒6.47
    Turner syndrome 11.41 2.973 20.367 2.948 16.865       3.153   5.38    1.1‒9.92
    Anemia 16.3 12.7 28.2 15.184 27.597     15.06   1.69  1.07‒2.78
    Vitamin B12 deficiency anemia 11.41 5.971 15.667 6.376 15.332       6.718   2.23  1.12‒4.29
    Folate deficiency anemia 4.89 6.729 12.533 8.808 12.265       8.342   1.25  1.17‒2.73
RR, relative risk; CI, confidence interval.
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with atopic dermatitis comprising 24.0% of atopic diseas-
es.19 Theoretically, as well as through experience, we be-
lieve that the pro-inflammatory status of atopic dermatitis 
might play as a predisposing factor for vitiligo. Also, con-
stant itching and scratching induced by eczema can induce 
Koebner effect on vitiligo. However, the prevalence of atop-
ic dermatitis concurrent with vitiligo, based on HIRA data, 
does raise a concern for overestimated diagnosis. Prescrip-
tion of topical pimecrolimus or tacrolimus, a frequently used 
agent for localized vitiligo, is classified as an uninsured drug 
in Korea to block their usage in off-label conditions, and di-
agnostic code of atopic dermatitis added to vitiligo patients 
for insurance claim is not uncommon. Also, with Korea’s 
increasing interest in outward appearances, awareness and 
screening of atopic dermatitis amongst Korean parents is 
sometimes beyond a necessary need. Children with hardly 
visible atopic lesions visit dermatology clinics with con-
cerns of lesions progressing in the future. Because the data 
used could not exclude these minor cases, overestimation 
of atopic dermatitis is entirely possible.
Another commonly associated comorbidities is psoriasis. 
However, association between vitiligo and psoriasis is con-
troversial. In a ten year retrospective study of comorbidities 
of vitiligo, psoriasis was the most common comorbidity in 
Asian population and the second most common disease in 
total population, followed by thyroiditis.1 On the other hand, 
a review of reports on vitiligo and psoriasis from 1968 to 
2010 revealed a relatively similar rate of psoriasis in vitili-
go patients compared to the rate of psoriasis in general pop-
ulation, suggesting that coexistence of psoriasis and vitiligo 
is probably due to coincidence.20 Yet, while the crude prev-
alence of psoriasis in general population of Korea in our 
data was 0.3% (data not shown), which is a rate close to the 
expected prevalence of psoriasis in Korea,21 the prevalence 
of psoriasis in vitiligo patients was higher at 1.78% (data 
not shown). 
Interestingly, adjusted RR of vitiligo in psoriatic patients 
using national database in Taiwan was 5.94,22 and our RR 
of psoriasis in vitiligo patients was 5.76. Although direct 
comparison of two RRs are not possible due to different 
methodologies used in each studies, increased rate of both 
vitiligo and psoriasis when associated with each other sug-
gests common genetic locus in major histocompatibility 
complex (MHC) of both diseases23 and shared pathogenic 
pathways through Th1, and Th17 pathways.24,25 
In addition, the majority of autoimmune diseases showed 
higher RRs than non-autoimmune disease group. Phenome-
For this study, we used data between 2009 and 2011 in the 
national health claim database obtained from the HIRA of 
Korea. The HIRA database contains information on entire 
Korea population that is related to all medical claims in Ko-
rea. Furthermore, because a unique identification number is 
used in the database (Korean Resident Registration Num-
ber) assigned at birth, we can rule out omissions or duplica-
tions in the records. 
Korea is one of few countries with little barriers in enter-
ing medical treatment, but it also has a popular medical cul-
ture of oriental medicine and alternative medicine (records 
from these medical communities were not included in our 
study). Patients attending oriental medical clinics, patients 
educated with beliefs that vitiligo is incurable and hence re-
fusing to visit hospitals, and non-dermatology trained doc-
tors failing to detect vitiligo, are all contributing factors for 
lower than expected prevalence of vitiligo which was de-
duced from medical claims data. 
Bimodal distribution was also comparable to other studies 
reported. The male to female ratio was 1 to 1.31 in Korea, a 
finding not too far-fetched from equal sex ratio known in lit-
erature.16 
In the present study, we identified prevalence of comor-
bidities associated with vitiligo. The largest review, per-
formed in Korea, on comorbidities assessed 1203 vitiligo 
patients visiting seven university-level tertiary referral hos-
pitals. In the study, there were 16.4% of patients with co-
existing thyroiditis, 10.4% with allergic disease (asthma, 
rhinitis, atopic dermatitis), and 9.7% with diabetes mellitus. 
However, no extensive searches on other autoimmune dis-
eases were done.17 In a similar skin phenotype group, 133 
Japanese patients with generalized vitiligo were investigat-
ed for occurrence of autoimmune diseases.18 In these pa-
tients, 20.3% had associated autoimmune disorders; Hashi-
moto’s thyroiditis (12%) was the most common disease, 
followed by alopecia areata (5.3%), and psoriasis (1.5%). 
We studied the rate per 100000 of the associated comor-
bidities, and most of the rates were lower than those shown 
in previous tertiary level studies. Nevertheless, the general 
trend of thyroiditis being one of the most prevalent diseases 
among vitiligo patients was obvious. 
In the present study, the rate of atopic dermatitis coincid-
ing with vitiligo was higher than expected, with prevalence 
of 5.53% in vitiligo patients (data not shown). In a prospec-
tive online-questionnaire for vitiligo patients at a single in-
stitution showed that out of 2848 patients, a total of 1635 
patients (61.8%) had history of at least 1 atopic disease 
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50593516 annual cases for 3 consecutive years, and it is by 
far the most comprehensive review on prevalence of vitili-
go. Our noted prevalence is within the range of those re-
ported in previous literatures, and there was also bimodal 
distribution with no difference in gender. Also, we found 
that prevalence of vitiligo in South Korea was associated 
with significantly increased risk of comorbidities such as 
thyroid diseases and psoriasis. The finding of these associa-
tions should aid clinicians in initial work up of vitiligo pa-
tients and concurrent follow ups. 
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